NCT05175833View on ClinicalTrials.gov

Oral Probiotics and Secondary Bacterial Pneumonia in Severe COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 11, 2020

Primary Completion Date

January 25, 2021

Study Completion Date

February 7, 2021

Conditions
COVID-19 Lower Respiratory InfectionMicrobial ColonizationSevere COVID-19Secondary Bacterial Pneumonia
Interventions
COMBINATION_PRODUCT

Oral probiotics

Oral gel containing streptococcus salivarius K12 and lactobacillus brevis CD2

OTHER

Oral placebo

Oral gel containing placebo

Trial Locations (1)

99010080

University of Passo Fundo, Passo Fundo

All Listed Sponsors
lead

Universidade de Passo Fundo

OTHER

NCT05175833 - Oral Probiotics and Secondary Bacterial Pneumonia in Severe COVID-19 | Biotech Hunter | Biotech Hunter